颅内自我刺激和运动痕迹作为评估和开发抗精神病药物的指标。

Intracranial self-stimulation and locomotor traces as indicators for evaluating and developing antipsychotic drugs.

作者信息

Takigawa M, Fukuzako H, Ueyama K, Tominaga H

机构信息

Health Service Center, Kagoshima University, Japan.

出版信息

Jpn J Psychiatry Neurol. 1994 Mar;48(1):127-32. doi: 10.1111/j.1440-1819.1994.tb03006.x.

DOI:10.1111/j.1440-1819.1994.tb03006.x

PMID:7933709

Abstract

When chlorpromazine (CPZ) and lithium chloride (LiCl) are compared, the former suppresses both rat's intracranial self-stimulation (ICSS) and methamphetamine (MAP)-induced hyperactivity. On the other hand, the latter suppresses only MAP-induced abnormal hyperactivity but hardly suppresses a purpose-oriented ICSS associated with the reward system. Therefore, LiCl inhibits abnormal hyperactivity induced by MAP, but it does not suppress physiological motivation. Using the two types of antipsychotic drugs, the authors propose a method of combining the ICSS and locomotor activity together with its traces. These proposals are useful indicators for evaluating and developing the new antipsychotic drugs which are used clinically for psychotic patients and for understanding the drug-induced akinesia and anhedonia.

摘要

当比较氯丙嗪（CPZ）和氯化锂（LiCl）时，前者会抑制大鼠的颅内自我刺激（ICSS）和甲基苯丙胺（MAP）诱导的多动。另一方面，后者仅抑制MAP诱导的异常多动，但几乎不抑制与奖赏系统相关的目标导向性ICSS。因此，LiCl抑制MAP诱导的异常多动，但不抑制生理动机。作者使用这两种抗精神病药物，提出了一种将ICSS和运动活动及其痕迹相结合的方法。这些提议对于评估和开发临床上用于精神病患者的新型抗精神病药物以及理解药物诱导的运动不能和快感缺失是有用的指标。